29 August 2024 in Hematological Oncology
Mantle cell lymphoma (MCL) is a rare and aggressive form of non‐Hodgkin lymphoma. Challenges in its treatment include relapse, drug resistance, and a short survival period. The Hedgehog/GLI1 (Hh/GLI1) and Wnt/β‐catenin pathways are crucial in cancer cell proliferation, survival, and drug resistance, making them significant targets for anticancer research. This study aimed to assess the effectiveness of combining inhibitors for both pathways against MCL and investigate the underlying molecular mechanisms. The co‐expression of key proteins from the Hh/GLI1 and Wnt/β‐catenin pathways was observed in MCL. Targeting the Hh/GLI1 pathway with the GLI1 inhibitor GANT61 and the Wnt/β‐catenin pathway with the CBP/β‐catenin transcription inhibitor ICG‐001, dual‐target therapy was demonstrated to synergistically suppressed the activity of MCL cells. This approach promoted MCL cell apoptosis, induced G0/G1 phase blockade, decreased the percentage of S‐phase cells, and enhanced the sensitivity of MCL cells to the drugs adriamycin and ibrutinib. Both GANT61 and ICG‐001 downregulated GLI1 and β‐catenin while upregulating GSK‐3β expression. The interaction between Hh/GLI1 and Wnt/β‐catenin pathways was mediated by GANT61‐dependent Hh/GLI1 inhibition. Moreover, GLI1 knockdown combined with ICG‐001 synergistically induced apoptosis and increased drug sensitivity of MCL cells to doxorubicin and ibrutinib. GANT61 attenuated the overexpression of β‐catenin and decreased the inhibition of GSK‐3β in MCL cells. Overall, the combined targeting of both the Hh/GLI1 and Wnt/β‐catenin pathways was more effective in suppressing proliferation, inducing G0/G1 cycle retardation, promoting apoptosis, and increasing drug sensitivity of MCL cells than mono treatments. These findings emphasize the potential of combinatorial therapy for treating MCL patients.
25 February 2026 in Journal of International Medical Research
Purpose: To investigate the association between Syndecan-2 gene methylation and protein expression dynamics in colorectal cancer and evaluate its clinicopathological significance. Methods: We analyzed 197 tissues (96 colorectal cancer, 64 adenoma, and 37 normal tissues). Syndecan-2 methylation was quantified using quantitative methylation-specific polymerase chain reaction, and protein expression was evaluated via immunohistochemistry. Results: Syndecan-2 methylation frequency was significantly higher in colorectal cancer (81.25%) and adenoma (64.06%) than in normal (5.41%) tissues. It showed high diagnostic accuracy for colorectal cancer (area under the curve = 0.88). Although methylation status was unrelated to most clinical parameters, higher methylation levels were correlated with poor tumor differentiation ( p = 0.022). Syndecan-2 protein was aberrantly expressed in tumor stroma but lacked clinical correlations. A significant positive correlation between methylation and protein expression was observed across the sample ( p < 0.05); however, this association was not maintained within the colorectal cancer subgroup specifically, showing no intrasample concordance (Kappa statistic = −0.046). Conclusion: Syndecan-2 methylation serves as a highly sensitive epigenetic biomarker for the early detection of colorectal cancer. The findings reveal a complex and heterogeneous relationship between Syndecan-2 methylation and its protein expression during colorectal cancer progression, suggesting stage-specific regulatory mechanisms. Further multiomics studies are warranted to elucidate the underlying functional dynamics.